Agios Pharmaceuticals (AGIO) Hits New 1-Year Low at $51.37

Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $51.37 and last traded at $56.03, with a volume of 32349 shares changing hands. The stock had previously closed at $54.05.

A number of research analysts have issued reports on AGIO shares. Cann reaffirmed a “hold” rating on shares of Agios Pharmaceuticals in a report on Wednesday, September 5th. Leerink Swann started coverage on shares of Agios Pharmaceuticals in a report on Monday, September 24th. They issued a “market perform” rating and a $80.00 target price for the company. ValuEngine cut shares of Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, September 11th. BidaskClub cut shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, September 19th. Finally, Guggenheim started coverage on shares of Agios Pharmaceuticals in a report on Monday, September 17th. They issued a “neutral” rating for the company. Six analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $96.27.

The stock has a market cap of $3.27 billion, a P/E ratio of -7.88 and a beta of 2.18.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($1.63) EPS for the quarter, missing the consensus estimate of ($1.62) by ($0.01). The business had revenue of $15.20 million during the quarter, compared to analyst estimates of $22.72 million. Agios Pharmaceuticals had a negative net margin of 461.78% and a negative return on equity of 48.51%. The firm’s revenue for the quarter was up 33.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.59) earnings per share. Analysts expect that Agios Pharmaceuticals Inc will post -6.12 earnings per share for the current fiscal year.

In related news, insider Scott Biller sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, October 5th. The shares were sold at an average price of $69.79, for a total transaction of $209,370.00. Following the sale, the insider now owns 53,932 shares in the company, valued at $3,763,914.28. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director John Maraganore sold 13,555 shares of the firm’s stock in a transaction that occurred on Tuesday, September 11th. The stock was sold at an average price of $72.75, for a total transaction of $986,126.25. Following the sale, the director now owns 38,609 shares in the company, valued at approximately $2,808,804.75. The disclosure for this sale can be found here. Insiders sold 19,555 shares of company stock worth $1,404,566 over the last quarter. Company insiders own 3.02% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in AGIO. Principal Financial Group Inc. boosted its position in Agios Pharmaceuticals by 11.5% during the first quarter. Principal Financial Group Inc. now owns 14,895 shares of the biopharmaceutical company’s stock worth $1,218,000 after acquiring an additional 1,533 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Agios Pharmaceuticals by 459.8% in the 2nd quarter. Wells Fargo & Company MN now owns 407,393 shares of the biopharmaceutical company’s stock valued at $34,315,000 after purchasing an additional 334,617 shares during the last quarter. Jennison Associates LLC boosted its holdings in shares of Agios Pharmaceuticals by 1.7% in the 2nd quarter. Jennison Associates LLC now owns 193,935 shares of the biopharmaceutical company’s stock valued at $16,335,000 after purchasing an additional 3,183 shares during the last quarter. Alps Advisors Inc. boosted its holdings in shares of Agios Pharmaceuticals by 11.5% in the 2nd quarter. Alps Advisors Inc. now owns 83,297 shares of the biopharmaceutical company’s stock valued at $7,016,000 after purchasing an additional 8,580 shares during the last quarter. Finally, Sei Investments Co. boosted its holdings in shares of Agios Pharmaceuticals by 255.6% in the 2nd quarter. Sei Investments Co. now owns 9,099 shares of the biopharmaceutical company’s stock valued at $767,000 after purchasing an additional 6,540 shares during the last quarter. Hedge funds and other institutional investors own 95.33% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was published by XNewsPress and is the sole property of of XNewsPress. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://xnewspress.com/news/2018/12/08/agios-pharmaceuticals-agio-hits-new-1-year-low-at-51-37.html.

Agios Pharmaceuticals Company Profile (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Featured Story: What are Institutional Investors?

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply